Prognosis of chronic hepatitis c: Results of a large, prospective cohort study

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Hepatology

• Publication date

  1998-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.510280632PMID 9828236
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: clinical and histological outcome.

  2008cited by this paper
• Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group.

  1999cited by this paper
• Risk Factors for Hepatocellular Carcinoma Among Chronic Hepatitis C Patients Treated with Interferon

  1999cited by this paper
• Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: Results of a case‐control study

  1997cited by this paper
• The natural history of chronic hepatitis C and what we should do about it.

  1997cited by this paper
• Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.

  1997cited by this paper
• Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

  1997cited by this paper
• Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C

  1997cited by this paper
• HCV genotypes in patients with liver disease of different stages and severity.

  1997cited by this paper
• Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP).

  1997cited by this paper
• Lack of sustained efficacy of interferon in patients with chronic hepatitis C.

  1996cited by this paper
• The natural course of chronic hepatitis C: A comparison between patients with genotypes 1 and 2 hepatitis C viruses

  1996cited by this paper
• Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: Clinical study of 26 cases

  1996cited by this paper
• Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon Therapy

  1996cited by this paper
• Retrospective analysis of the effect of interferon therapy on hepatocellular carcinoma (HCC) development in cirrhosis

  1996cited by this paper
• Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group.

  1996cited by this paper
• Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

  1996cited by this paper
• The long‐term pathological evolution of chronic hepatitis C

  1996cited by this paper
• Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study.

  1996cited by this paper
• Presentation of hepatitis C in a unique uniform cohort 17 years from inoculation

  1995cited by this paper
• Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities

  1995cited by this paper
• Epidemiology of genotypes of hepatitis C virus in Japanese patients with type C chronic liver diseases: A multi‐institution analysis

  1995cited by this paper
• Clinical outcomes after transfusion-associated hepatitis C.

  1995cited by this paper
• Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group.

  1995cited by this paper
• Hepatitis C virus genotypes and development of hepatocellular carcinoma

  1995cited by this paper
• Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

  1995cited by this paper
• HCV-associated liver cancer without cirrhosis.

  1995cited by this paper
• Hepatitis C Virus Type 1b (II) Infection in France and Italy

  1995cited by this paper
• Hepatitis C and Hepatocellular Carcinoma

  1995cited by this paper
• Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease.

  1994cited by this paper
• Hepatitis C virus genotypes: An investigation of type‐specific differences in geographic origin and disease

  1994cited by this paper
• Degree of diversity of hepatitis C virus quasispecies and progression of liver disease

  1994cited by this paper
• Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin.

  1994cited by this paper
• A proposed system for the nomenclature of hepatitis C viral genotypes

  1994cited by this paper
• Hepatitis C virus genotypes, reactivity to recombinant immunoblot assay 2 antigens and liver disease

  1994cited by this paper
• Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease

  1993cited by this paper
• Quantification of hepatitis C virus by competitive reverse transcription—polymerase chain reaction: Increase of the virus in advanced liver disease

  1993cited by this paper
• A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis

  1993cited by this paper
• Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second Decade

  1993cited by this paper
• Natural course of chronic hepatitis C.

  1993cited by this paper
• Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis.

  1993cited by this paper
• Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis

  1992cited by this paper
• Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group.

  1992cited by this paper
• Severity of liver disease with different hepatitis C viral clones.

  1991cited by this paper
• Long‐term clinical and histopathological follow‐up of chronic posttransfusion hepatitis

  1991cited by this paper
• Severity of liver disease with different hepatitis C viral clones

  1991cited by this paper
• Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis.

  1982cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Bothropstoxins I and II as potent phospholipase A2 molecules from Bothrops jararacussu to impair Hepatitis C virus infection.

  2025cites this paper
• Practical applications of AI in body imaging

  2025cites this paper
• Hepatitis C Virus Cascade of Care After the Introduction of Direct-Acting Antiviral Medications in Suriname

  2025cites this paper
• Viral eradication reduces all‐cause mortality in patients with chronic hepatitis C virus infection who had received direct‐acting antiviral therapy

  2024cites this paper
• Épidémiologie et facteurs de risque de la maladie du foie liée à l’alcool

  2024cites this paper
• Craniocerebral Metastases of Hepatocellular Carcinoma

  2023cites this paper
• Alcool et virus

  2023cites this paper
• Comparison of postoperative outcomes in cases achieving sustained virological response with direct‐acting antiviral and interferon therapy

  2023cites this paper
• The metabolic fingerprint of chronic hepatitis C progression: Metabolome shifts and cutting‐edge diagnostic options

  2023cites this paper
• Pathogenesis of Oncoviruses: A Systemic Review

  2023cites this paper
• Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy

  2023cites this paper
• No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy.

  2022cites this paper
• Probing a Stochastic Epidemic Hepatitis C Virus Model with a Chronically Infected Treated Population

  2022cites this paper
• Diagnostic performance of liver fibrosis assessment by quantification of liver surface nodularity on computed tomography and magnetic resonance imaging: systematic review and meta-analysis

  2022cites this paper
• Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study

  2022influential citation
• Liquid biopsy for early detection and therapeutic monitoring of hepatocellular carcinoma

  2022cites this paper
• The Bank Vole (Clethrionomys glareolus)—Small Animal Model for Hepacivirus Infection

  2021cites this paper
• Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis

  2021cites this paper
• Association of Adiponutrin/Patatin Like Phospholipase 3 (PNPLA3) I148M Gene Variant with Chronic Hepatitis C in Egyptian Children

  2021cites this paper
• Risk Factors for Hepatocellular Carcinoma: A Historical Perspective

  2021cites this paper
• Incidence and Clinical Features of Hepatitis C Virus-associated Hepatocellular Carcinoma Patients without Liver Cirrhosis in Hepatitis B Virus-endemic Area

  2021cites this paper
• Compositional distinction of gut microbiota between Han Chinese and Tibetan populations with liver cirrhosis

  2021cites this paper
• Prevalence of liver fibrosis and associated risk factors in the Korean general population: a retrospective cross-sectional study

  2021cites this paper
• Long-term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: an analysis using a Markov chain model.

  2020cites this paper
• Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis

  2020cites this paper
• Hepatocellular Carcinoma in Oman

  2020cites this paper
• Liver-related effects of chronic hepatitis C antiviral treatment

  2020cites this paper
• Capsaicin-loaded solid lipid nanoparticles: design, biodistribution, in silico modeling and in vitro cytotoxicity evaluation

  2020cites this paper
• Effect of Peroxisome Proliferator-Activated Receptor-γ Coactivator-1 Alpha Variants on Spontaneous Clearance and Fibrosis Progression during Hepatitis C Virus Infection in Moroccan Patients

  2020cites this paper
• Real‐world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus‐related decompensated cirrhosis

  2020cites this paper
• Impact of viral eradication by direct‐acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus‐related compensated cirrhosis patients

  2020cites this paper
• Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen

  2019cites this paper
• Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases—meta‐analytic assessment

  2019cites this paper
• Natural history of liver‐related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model

  2019cites this paper
• Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction.

  2019cites this paper
• A twenty gene-based gene set variation score reflects the pathological progression from cirrhosis to hepatocellular carcinoma

  2019cites this paper
• A Predictive Scoring Model for Relapse in Chronic HCV Patients with Rapid Virologic Response to PEG Interferon / Ribavirin Treatment

  2019cites this paper
• Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients

  2019cites this paper
• Sixteen-year Prognosis of Treatment-naive Patients with Hepatitis C Infection

  2019cites this paper
• S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“

  2018cites this paper
• The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1

  2018cites this paper
• Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies

  2018cites this paper
• Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group

  2018cites this paper
• Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B‐endemic area

  2018cites this paper
• PNPLA3 Polymorphism Directly Affects the Susceptibility of Genotype 4-Induced HCV Infection and Its Progression to Liver Fibrosis Among the Egyptian Patients

  2018cites this paper
• Mixed Imaging on Port-Venous Phase of Contrast-Enhanced Dual-Source Dual-Energy Computed Tomography: A Measurement Method Based on Couinaud Segments

  2018cites this paper
• Race affects SVR12 in a large and ethnically diverse hepatitis C‐infected patient population following treatment with direct‐acting antivirals: Analysis of a single‐center Department of Veterans Affairs cohort

  2018cites this paper
• On the Front Lines: Hepatitis C Infection in Primary Care.

  2018cites this paper
• Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all‐oral direct‐acting antiviral regimens

  2018cites this paper
• The impact of interferon‐free direct‐acting antivirals on clinical outcome after curative treatment for hepatitis C virus–associated hepatocellular carcinoma: Comparison with interferon‐based therapy

  2018cites this paper
• Reactivation of Hepatitis B Virus During Treatment of Hepatitis C Genotype 3 with Daclatasvir and Sofosbuvir in a Patient with Dual Infection of Hepatitis B and Hepatitis C Virus

  2018cites this paper
• Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates

  2018cites this paper
• [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection].

  2018cites this paper
• Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study

  2018cites this paper
• Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety

  2018cites this paper
• Hepatitis B and C Coinfection

  2018cites this paper
• [Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012].

  2018cites this paper
• Advanced liver fibrosis effects on the response to sofosbuvir‐based antiviral therapies for chronic hepatitis C

  2018cites this paper
• Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction

  2017cites this paper
• Hepatitis C virus infection

  2017cites this paper
• Increase in albumin by daclatasvir/asunaprevir therapy is correlated with decrease in aspartate transaminase

  2017cites this paper
• Emergence of drug resistance‐associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir‐treated chronic hepatitis C patients

  2017cites this paper
• The diagnosis and treatment of hepatocellular carcinoma.

  2017cites this paper
• Evidence for Health Decision Making — Beyond Randomized, Controlled Trials: The Changing Face of Clinical Trials

  2017cites this paper
• Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease

  2017cites this paper
• Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection

  2017cites this paper
• The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C‐infected patients treated with direct‐acting antivirals with and without pegylated interferon: A Belgian experience

  2017cites this paper
• EFFECT OF HEPATITIS C VIRUS ON HAEMOGLOBIN AND HAEMATOCRIT LEVELS IN ABUTH AND AKTH HAEMODIALYSIS PATIENTS

  2017cites this paper
• Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C

  2017cites this paper
• Serum Wisteria floribunda Agglutinin Positive Mac-2-Binding Protein and Fib-4 Index on the Clinical Course of Patients with Chronic Hepatitis C Receiving Daclatasvir/Asunaprevir Therapy

  2017cites this paper
• The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy

  2017cites this paper
• Hepatocellular Carcinoma After Sustained Virologic Response: Leave No One Behind.

  2017cites this paper
• Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa?

  2017cites this paper
• The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir

  2017cites this paper
• Hepatocellular Carcinoma: Epidemiology, Basic Principles of Treatment, and Clinical Data

  2017cites this paper
• The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis

  2017cites this paper
• Direct-acting antivirals (daas) increase the serum vegf level in patients with chronic hepatitis c: a rationale for tumor recurrence

  2017cites this paper
• Characterization of fibrosis changes in chronic hepatitis C patients after virological cure: A systematic review with meta‐analysis

  2017cites this paper
• Roles of p53 in extrinsic factor-induced liver carcinogenesis

  2017cites this paper
• COINFECTION WITH HEPATITIS B AND HEPATITIS C VIRUS: NEW INSIGHTS OF TREATMENT IN THE ERA OF DIRECT ACTING ANTIVIRALS.

  2017cites this paper
• ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C

  2017cites this paper
• The oncologic burden of hepatitis C virus infection: A clinical perspective

  2017cites this paper
• Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2

  2017cites this paper
• To Study the Clinical Profile and Viral Markers (Hepatitis B and C) In Acute and Chronic Liver Disease

  2017cites this paper
• IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C

  2017cites this paper
• Real‐world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus‐infected cirrhosis patients

  2017cites this paper
• Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice.

  2016cites this paper
• Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index

  2016cites this paper
• Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C.

  2016cites this paper
• From THE DEPARTMENT OF MEDICINE, SOLNA Karolinska Institutet, Stockholm, Sweden CHRONIC HEPATITIS MORBIDITY AND MORTALITY IN PATIENTS AND THEIR CHILDREN

  2016cites this paper
• Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg‐interferon, and ribavirin combination treatment for chronic hepatitis C

  2016cites this paper
• Improvement of renal dysfunction in a patient with hepatitis C virus‐related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report

  2016cites this paper
• Mortality in patients with Chronic Hepatitis C and cirrhosis compared to the general population – a Danish cohort study

  2016cites this paper
• Role of dual energy spectral computed tomography in characterization of hepatocellular carcinoma: Initial experience from a tertiary liver care institute

  2016cites this paper
• Biochemical Evaluation of the Metabolic Abnormalities Associating with Hepatitis C virus Patients

  2016cites this paper
• Hepatocellular Carcinoma Screening and Surveillance: Practice Guidelines and Real-Life Practice

  2016cites this paper
• The Natural History of Hepatit is C Viral Infection: Clinical Evaluation and Monitoring

  2016cites this paper
• Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.

  2016cites this paper
• Impact of aldo‐keto reductase family 1 member B10 on the risk of hepatitis C virus‐related hepatocellular carcinoma

  2016cites this paper
• Natural history of chronic hepatitis C

  2016cites this paper